Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Starboard, Kenvue
Kenvue needs to fix its skin, health & beauty segments, Starboard's Jeff Smith says (update)
Adds Kenvue comment. Kenvue (NYSE:KVUE) needs to focus on fixing its skin, health and beauty segments, Jeff Smith, founder and CEO of activist hedge fund Starboard Value said. "We are having conversations with them and there are signs that Kenvue is already going in the right direction,
Starboard says Kenvue's skin health segment is weighing on performance
Starboard Value called consumer products company Kenvue a bargain and said its skin health and beauty segment's lackluster growth is the reason for the stock's underperformance. Starboard Chief Investment Officer Jeffrey Smith said there is an opportunity to improve revenue growth and margins at the segment which has the Neutrogena and Aveeno brands.
Starboard Targets Another Health Company. Why Kenvue Is in Its Sights.
Tylenol, Listerine and Band-Aid maker Kenvue is the latest in the health related sector to attract an activist investor. And not just any corporate agitator, Starboard Value, which in recent days targeted pharma giant Pfizer.
Pfizer, Starboard Value
Starboard Value CEO Jeff Smith: Pfizer needs to do a better job disciplining itself on investments
Jeff Smith, Starboard Value CEO, joins CNBC's 'Squawk on the Street' to discuss how he sees Pfizer going forward, potential for growth in Kenvue, and more.
Starboard Value CEO says Pfizer's board should hold management accountable
Activist hedge fund Starboard Value's chief investment officer Jeffrey Smith said on Tuesday that drugmaker Pfizer Inc's board needs to hold management accountable for its underperformance. "We measure success in producing blockbuster drugs and we all get measured by our track records.
Starboard Chief Criticizes Pfizer’s R&D Investments
Activist hedge fund Starboard Value believes the root cause of Pfizer’s issues are the low expected returns on its research and development investments, including investments done both internally and through mergers and acquisitions.
22h
What activist hedge fund Starboard wants from Pfizer
Starboard's Jeff Smith told Pfizer in a meeting last week that they need to improve their return on investments in R&D and ...
21h
Starboard calls for Pfizer board to ‘hold management accountable’
Jeff Smith says pharma giant’s returns from recent efforts are ‘not adequate’ in speech at 13D activist investor conference ...
FiercePharma
22h
UPDATED: Starboard wants to hold Pfizer leadership 'accountable' for overpaid M&A deals, poor return on R&D investment
Activist investor Starboard Value is baring its teeth at Pfizer management, more openly going after CEO Albert Bourla’s job.
pharmaphorum
6h
Starboard spells out its concerns with Pfizer's direction
Despite that cash windfall, Pfizer has "dramatically underperformed its peers and the market since 2019," according to ...
BioSpace
23h
Activist Investor Starboard Takes Aim at J&J Spinoff Kenvue on Heels of $1B Stake in Pfizer
Starboard Value contends that Kenvue, with strong consumer health brands like Tylenol and Listerine, is underperforming its ...
FiercePharma
1d
Activist investor Starboard sets its sights on J&J spinout Kenvue: WSJ
Activist investor Starboard Value, which picked up a $1 billion stake in Pfizer earlier this month, now reportedly has ...
1d
on MSN
Tylenol Maker Kenvue Stock Surges on Report Starboard Takes 'Sizable Stake'
Activist investor Starboard Value reportedly has taken a large stake in consumer health products maker Kenvue.
1d
on MSN
Activist Starboard could push for Kenvue to sell some/all of its SHB business - analyst
Financial writer highlights activist investor Starboard Value's push for Kenvue (KVUE) to divest its challenged skin, ...
EconoTimes
2d
Starboard Value Acquires Stake in Kenvue, Pushes for Stock Price Boost
Starboard Values Investment in Kenvue Inc. Activist hedge fund Starboard Value has taken a sizeable stake in Kenvue Inc., ...
10h
Starboard Focused on Kenvue's Struggling Unit
Starboard Chief Executive Jeff Smith said that Kenvue, the Tylenol-maker spun out from Johnson & Johnson, should drill down on fixing its underperforming skin health and beauty segment, which he ...
2d
Activist investor Starboard takes stake in Kenvue - WSJ
Financial writer reports activist investor Starboard Value's stake in Kenvue Inc., seeking measures to boost stock price.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Kenvue
Pfizer
The Wall Street Journal
Tylenol
Johnson & Johnson
Feedback